Literature DB >> 20005921

CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid.

Vilmantas Giedraitis1, Anna Glaser, Timo Sarajärvi, RoseMarie Brundin, Malin Degerman Gunnarsson, Brit-Maren Schjeide, Rudolph E Tanzi, Seppo Helisalmi, Tuula Pirttilä, Lena Kilander, Lars Lannfelt, Hilkka Soininen, Lars Bertram, Martin Ingelsson, Mikko Hiltunen.   

Abstract

Recently, the P86L alteration in CALHM1 (calcium homeostasis modulator-1) was reported to be associated with Alzheimer's disease (AD). Moreover, the risk allele increased amyloid-beta (A beta) levels in conditioned media from cultured cells. Therefore, we hypothesized that CALHM1 P86L may modulate A beta or tau levels in cerebrospinal fluid (CSF). Nearly 200 individuals with AD or other cognitive disorders were included for CSF analysis and CALHM1 genotyping. No significant differences in CSF levels of A beta 42, tau or phospho-tau were found across the various CALHM1 genotypes. In conclusion, we found no evidence that CALHM1 P86L is associated with altered CSF levels of the investigated AD biomarkers. (c) 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20005921      PMCID： PMC2860374          DOI： 10.1016/j.neulet.2009.12.011

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN： 0304-3940            Impact factor:   3.046


  12 in total

1.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database.

Authors:  Lars Bertram; Matthew B McQueen; Kristina Mullin; Deborah Blacker; Rudolph E Tanzi
Journal:  Nat Genet       Date:  2007-01       Impact factor: 38.330

2.  A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk.

Authors:  Ute Dreses-Werringloer; Jean-Charles Lambert; Valérie Vingtdeux; Haitian Zhao; Horia Vais; Adam Siebert; Ankit Jain; Jeremy Koppel; Anne Rovelet-Lecrux; Didier Hannequin; Florence Pasquier; Daniela Galimberti; Elio Scarpini; David Mann; Corinne Lendon; Dominique Campion; Philippe Amouyel; Peter Davies; J Kevin Foskett; Fabien Campagne; Philippe Marambaud
Journal:  Cell       Date:  2008-06-27       Impact factor: 41.582

3.  Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.

Authors:  Trey Sunderland; Nadeem Mirza; Karen T Putnam; Gary Linker; Deepa Bhupali; Rob Durham; Holly Soares; Lida Kimmel; David Friedman; Judy Bergeson; Gyorgy Csako; James A Levy; John J Bartko; Robert M Cohen
Journal:  Biol Psychiatry       Date:  2004-11-01       Impact factor: 13.382

4.  Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease.

Authors:  T Tapiola; T Pirttilä; P D Mehta; I Alafuzofff; M Lehtovirta; H Soininen
Journal:  Neurobiol Aging       Date:  2000 Sep-Oct       Impact factor: 4.673

5.  No association between CALHM1 and Alzheimer's disease risk.

Authors:  Lars Bertram; Brit-Maren M Schjeide; Basavaraj Hooli; Kristina Mullin; Mikko Hiltunen; Hilkka Soininen; Martin Ingelsson; Lars Lannfelt; Deborah Blacker; Rudolph E Tanzi
Journal:  Cell       Date:  2008-12-12       Impact factor: 41.582

6.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

7.  PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.

Authors:  N M Kemppainen; S Aalto; I A Wilson; K Någren; S Helin; A Brück; V Oikonen; M Kailajärvi; M Scheinin; M Viitanen; R Parkkola; J O Rinne
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

8.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

9.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

Authors:  D Galasko; L Chang; R Motter; C M Clark; J Kaye; D Knopman; R Thomas; D Kholodenko; D Schenk; I Lieberburg; B Miller; R Green; R Basherad; L Kertiles; M A Boss; P Seubert
Journal:  Arch Neurol       Date:  1998-07

10.  Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease.

Authors:  Annica Johansson; Hagit Katzov; Henrik Zetterberg; Lars Feuk; Boo Johansson; Nenad Bogdanovic; Niels Andreasen; Boris Lenhard; Anthony J Brookes; Nancy L Pedersen; Kaj Blennow; Jonathan A Prince
Journal:  Hum Genet       Date:  2004-03-18       Impact factor: 4.132
View more
  8 in total

1.  Generation of Calhm1 knockout mouse and characterization of calhm1 gene expression.

Authors:  Junbing Wu; Shengyi Peng; Rong Wu; Yumin Hao; Guangju Ji; Zengqiang Yuan
Journal:  Protein Cell       Date:  2012-06-21       Impact factor: 14.870

2.  CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease.

Authors:  Jeremy Koppel; Fabien Campagne; Valérie Vingtdeux; Ute Dreses-Werringloer; Michael Ewers; Dan Rujescu; Harald Hampel; Marc L Gordon; Erica Christen; Julien Chapuis; Blaine S Greenwald; Peter Davies; Philippe Marambaud
Journal:  Mol Med       Date:  2011-05-24       Impact factor: 6.354

3.  CALHM1 ion channel elicits amyloid-β clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain.

Authors:  Valérie Vingtdeux; Pallavi Chandakkar; Haitian Zhao; Lionel Blanc; Santiago Ruiz; Philippe Marambaud
Journal:  J Cell Sci       Date:  2015-05-21       Impact factor: 5.285

4.  Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels.

Authors:  John S K Kauwe; Carlos Cruchaga; Sarah Bertelsen; Kevin Mayo; Wayne Latu; Petra Nowotny; Anthony L Hinrichs; Anne M Fagan; David M Holtzman; Alison M Goate
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

5.  CALHM1 controls the Ca²⁺-dependent MEK, ERK, RSK and MSK signaling cascade in neurons.

Authors:  Ute Dreses-Werringloer; Valérie Vingtdeux; Haitian Zhao; Pallavi Chandakkar; Peter Davies; Philippe Marambaud
Journal:  J Cell Sci       Date:  2013-01-23       Impact factor: 5.285

6.  Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation.

Authors:  John S K Kauwe; Matthew H Bailey; Perry G Ridge; Rachel Perry; Mark E Wadsworth; Kaitlyn L Hoyt; Lyndsay A Staley; Celeste M Karch; Oscar Harari; Carlos Cruchaga; Benjamin J Ainscough; Kelly Bales; Eve H Pickering; Sarah Bertelsen; Anne M Fagan; David M Holtzman; John C Morris; Alison M Goate
Journal:  PLoS Genet       Date:  2014-10-23       Impact factor: 5.917

7.  Effect of the CALHM1 G330D and R154H human variants on the control of cytosolic Ca2+ and Aβ levels.

Authors:  Valérie Vingtdeux; Jessica E Tanis; Pallavi Chandakkar; Haitian Zhao; Ute Dreses-Werringloer; Fabien Campagne; J Kevin Foskett; Philippe Marambaud
Journal:  PLoS One       Date:  2014-11-11       Impact factor: 3.240

8.  CALHM1 deficiency impairs cerebral neuron activity and memory flexibility in mice.

Authors:  Valérie Vingtdeux; Eric H Chang; Stephen A Frattini; Haitian Zhao; Pallavi Chandakkar; Leslie Adrien; Joshua J Strohl; Elizabeth L Gibson; Makoto Ohmoto; Ichiro Matsumoto; Patricio T Huerta; Philippe Marambaud
Journal:  Sci Rep       Date:  2016-04-12       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.